Clinical trials: Rituximab, completed
LYMPHOMA
Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia
RIPAL is a prospective cohort study, which main goal is to define T and B immune repertoire diversity and magnitude in patients with non-Hodgkin lymphoma of high and low grade and chronic lymphocytic leukemia before and after…
- Trial name
- RIPAL (NCT02520895)
- Testing
- blood samplings
- Where
- France
- Volunteers
- 98 people
- Sponsor
- Hospices Civils de Lyon
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.
This single arm study will assess the safety and efficacy of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response or intolerance to one or more anti-TNF agents.
- Trial name
- NCT00504777
- Testing
- rituximab [MabThera/Rituxan], Methotrexate
- Where
- 10 sites in Taiwan
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
This phase I trial studies the side effects and best dose of ibrutinib when given together with rituximab, ifosfamide, carboplatin, and etoposide (combination chemotherapy) in treating patients with diffuse large B-cell lymphoma…
- Conditions
- CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT02219737
- Testing
- Carboplatin, Etoposide, Ibrutinib
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Membranous Nephropathy, Minimal Change Disease (MCD)
Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome
Immunophenotyping profiling of patients with primary MN, primary FSGS and MCD. Evaluation of these immune cell subsets as possible biomarkers to track response to treatment or disease relapse.
- Conditions
- Membranous Nephropathy, Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT07702981
- Testing
- Rituximab (MABTHERA® or RITUXAN®)., Corticosteroids (CS)
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ioannina
Chronic Lymphocytic Leukemia
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
Most cases of Chronic lymphocytic leukemia (CLL) remain an incurable disease with the goal of therapy being to improve quality of life and to prolong survival.
- Trial name
- NCT06362044
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- AbbVie
Myasthenia Gravis
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
The specific primary objective of this study is to determine whether rituximab is a safe and beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III efficacy trial.
- Trial name
- NCT02110706
- Testing
- Rituximab
- Where
- 26 sites in United States
- Volunteers
- 52 people
- Sponsor
- Yale University
Multicentric Castleman Disease
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
The purpose of this study is to determine the safety and efficacy of first-line, risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a single-arm, phase II clinical trial.
- Trial name
- NCT04585893
- Testing
- Rituximab, Etoposide
- Where
- Malawi
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphoma, Non-Hodgkin
Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma
This study will further characterize the activity of Tositumomab and Iodine I 131-Tositumomab in patients with relapsed indolent non-Hodgkin's Lymphoma who have progressed following treatment with rituximab.
- Trial name
- NCT00240565
- Testing
- Tositumomab 450 mg, Tositumomab 35 mg
- Where
- 11 sites in Canada
- Volunteers
- 93 people
- Sponsor
- GlaxoSmithKline
Follicular Lymphoma
Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab
Purpose of this study was to assess the safety profile and the anti-lymphoma activity of the FC+R combination.
- Trial name
- NCT00393107
- Testing
- rituximab, rituximab,fludarabine, cyclophosphamide
- Where
- 9 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Gruppo Italiano Studio Linfomi
Lymphoma
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies such as yttrium Y90 ibritumomab tiuxetan can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00058292
- Testing
- filgrastim, rituximab, Carmustine
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
Lymphoma
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00070447
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 87 sites in United States, Australia and 3 more
- Sponsor
- National Cancer Institute (NCI)
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
This randomized phase II trial is studying how well giving combination chemotherapy together with rituximab works in treating patients with HIV-associated stage I, stage II, stage III, or stage IV non-Hodgkin's lymphoma.
- Conditions
- AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma
- Trial name
- NCT00049036
- Testing
- rituximab, etoposide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant helps stop the growth of cancer cells by stopping them from dividing or by killing them.
- Trial name
- NCT00521014
- Testing
- filgrastim, rituximab, sargramostim
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is a Phase 1b, open-label, multicenter study evaluating the safety and tolerability of ABT-199 in combination with rituximab in up to 50 subjects with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
- Trial name
- NCT01682616
- Testing
- ABT-199, Rituximab
- Where
- 6 sites in United States, Australia
- Volunteers
- 49 people
- Sponsor
- AbbVie
Lymphoma, B-Cell, Lymphoma, Large-Cell, Diffuse
A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma
This Phase II study randomized R-ACVBP and R-CHOP as induction treatment in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI.
- Trial name
- LNH2007-3B (NCT00498043)
- Testing
- R-CHOP14 induction regimen, R-ACVBP14 induction regimen
- Where
- France
- Volunteers
- 222 people
- Sponsor
- Hospices Civils de Lyon
Mantle Cell Lymphoma, Lymphoma
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
The purpose of this study is to test the safety of Venetoclax in combination with FDA approved treatments Bendamustine, Rituximab and Ibrutinib (BR-I).
- Trial name
- NCT03295240
- Testing
- BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax)
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Cancer, Solid Tumor
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
- Conditions
- Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma
- Trial name
- NCT03013218
- Testing
- Evorpacept (ALX148), Pembrolizumab, Trastuzumab
- Where
- 10 sites in United States, South Korea
- Volunteers
- 174 people
- Sponsor
- ALX Oncology Inc.
Lymphoma, Follicular
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
This study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a…
- Trial name
- NCT02569996
- Testing
- Rituximab
- Where
- 21 sites in Hungary
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Cognitive Impairment, Autoimmune Encephalitis
To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI
Most of patients with autoimmune encephalitis are left with permanent cognitive deficits of varying severity. The patients' life and career would be affected definitely by cognitive deficits.
- Trial name
- NCT03530462
- Testing
- rituximab, cyclophosphamide, Steroids
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Lymphoma, B-Cell
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
The purpose of this study is to determine whether using high-dose chemotherapy, monoclonal antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients with high-risk Non-Hodgkin's Lymphoma (NHL).
- Trial name
- NCT00577629
- Testing
- cyclophosphamide, etoposide, rituximab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.